Drug Development
Avi BioPharma delays release of hepatitis C virus trial data
Published in Hepatitis Weekly, May 15th, 2006
The trial is designed to assess the safety, tolerability, pharmacokinetics (PK) and viral response to treatment with Avi's proprietary NeuGene antisense compound Avi-4065 among healthy volunteers and patients with HCV.
The first phase of this study was reported preliminarily in January 2006 and completed in March 2006. The trial evaluated 31 healthy volunteers who received 14 consecutive days of treatment of Avi-4065 at three dosage levels. Data from the second phase of the study, assessing HCV...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-05-15)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
HBV infection resolution involves functionally and phenotypically defined memory T cells - Hepatitis B Virus
HBV replication is regulated by cccDNA-bound histone acetylation status - Hepatitis B Virus
HBV surface antigen partial delipidation improves T cell antigenicity - Hepatitis C Virus
Hepatitis C virus core gene stimulates anti-core cytotoxic T lymphocyte activity - Hepatocellular Carcinoma
HCV-associated hepatocellular carcinoma involves deregulation of an RNA helicase - Adverse Drug Reaction
Adverse events after hepatitis A/B combination vaccine reported - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
